Treatment with platelet- and extracellular vesicle-rich plasma in otorhinolaryngology-a review and future perspectives

Vozel, Domen; Božič, Darja; Jeran, Marko; Jan, Zala; Pajnič, Manca; Pađen, Ljubiša; Uršič, Bojana; Iglič, Aleš; Kralj‐Iglič, Veronika; Battelino, Saba

doi:10.1016/bs.abl.2020.05.003

Cited by 4 publications

(10 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the CPTBCI treatment outcomes and identification of EVs in PVRP ( Figure 5 ), it is believed that EVs, along with platelets, positively impact the regenerative properties of PVRP ( Guo et al, 2017 ). It has been reported that platelet-derived EVs play significant roles in tissue regeneration, hemostasis, and immune response ( Vozel et al, 2020b ). A twofold mechanism could mediate these roles.…”

Section: Discussionmentioning

confidence: 99%

“…By mediating interactions between cells, EVs carry signaling molecules for phenotypic transformation and serve as a cell mechanism to get rid of unwanted constituents ( Ogorevc et al, 2014 ). In addition, platelet-derived EVs encapsulate principal growth factors from platelets ( Guo et al, 2017 ) and are especially rich in TFG-β (transforming growth factor beta), bFGF (basic fibroblast growth factor), PDGF (platelet-derived growth factor), and VEGF (vascular endothelial growth factor) ( Vozel et al, 2020b ). Regenerative roles of platelet-derived EVs from PVRP were confirmed in a recent in vitro study by Otahal et al (2020) , where the induction of chondrogenic gene expression in chondrocytes and prevention of the release of proinflammatory cytokines were found.…”

Section: Discussionmentioning

confidence: 99%

“…The above-listed properties of EVs could explain the regenerative, hemostatic, and immunological roles of PVRP in the treatment of CPTBCI. These roles could be regulated by choosing an appropriate PVRP activation procedure (i.e., exogenous or endogenous) and optimizing PVRP preparation protocol since the formation of EVs depends on in vivo or ex vivo platelet shedding ( Vozel et al, 2020b ).…”

Section: Discussionmentioning

confidence: 99%

“…PVRP: platelet- and extracellular vesicle-rich plasma; PPP: platelet-poor plasma. Adapted from Vozel et al (2020b) .…”

Section: Methodsmentioning

confidence: 99%

“…On the other hand, the platelet-rich plasma (PRP) has been widely used to promote wound healing in many clinical settings, recently in skull-base reconstruction ( Khafagy et al, 2018 ), nasal septal surgery, tonsillectomy ( Gökçe Kütük and Özdaş, 2019 ), and laryngectomy ( Eid et al, 2020 ) due to beneficial immune, hemostatic, and regenerative effects of platelets exerted by the release of growth factors from granules and several extra-granular molecules. Despite that, research, such as PRP in otorhinolaryngology, lacks randomized controlled clinical trials ( Pachito et al, 2019 ; Vozel et al, 2020b ). As plasma contains extracellular vesicles (EVs), which are considered to be important healing vectors, we refer to the preparation as platelet- and extracellular vesicle-rich plasma (PVRP) in this study ( Tao et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Autologous Platelet- and Extracellular Vesicle-Rich Plasma Is an Effective Treatment Modality for Chronic Postoperative Temporal Bone Cavity Inflammation: Randomized Controlled Clinical Trial

Vozel

Božič

Jeran

et al. 2021

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

PurposeTo determine the efficacy of autologous platelet- and extracellular vesicle-rich plasma (PVRP) to treat chronic postoperative temporal bone cavity inflammation (CPTBCI) after exhausting surgical and standard conservative therapies.Materials and MethodsPatients were randomly allocated to treatment with PVRP (PVRP group) or standard conservative methods (control group) in a setting of four once-monthly checkups and subsequent follow-up. The treatment outcome was measured with the Chronic Otitis Media Questionnaire-12 (COMQ-12), CPTBCI focus surface area, and CPTBCI symptom-free time after the fourth checkup.ResultsEleven patients from each group completed the trial; 95% of patients suffered from chronically discharging mastoid cavity (the type of CPTBCI). Within four checkups, the COMQ-12 score decreased statistically significantly in the PVRP group (p < 0.001) but not in the control group (p = 0.339). The CPTBCI foci surface area decreased statistically significantly between the first and second checkups (p < 0.0005) but not between other checkups (p > 0.05) in the PVRP group. No statistically significant differences in CPTBCI foci surface area were detected between checkups in the control group (p = 0.152). Nine patients from the PVRP group and three patients from the control group were CPTBCI symptom-free at the fourth checkup. The median symptom-free time was 9.2 months (95% CI [7.4, 11.9]) in the PVRP group. Cumulatively, 49% of patients in the PVRP group remained CPTBCI symptom-free for 12.7 months after the fourth checkup.ConclusionAutologous PVRP represents a novel additional and successful treatment modality for a chronically discharging radical mastoid cavity when the surgical and standard conservative treatment methods have been exhausted.Trial Numberhttps://clinicaltrials.gov (NCT04281901).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…PVRP: platelet- and extracellular vesicle-rich plasma; PPP: platelet-poor plasma. Adapted from Vozel et al (2020b) .…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Autologous Platelet- and Extracellular Vesicle-Rich Plasma Is an Effective Treatment Modality for Chronic Postoperative Temporal Bone Cavity Inflammation: Randomized Controlled Clinical Trial

Vozel

Božič

Jeran

et al. 2021

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

show abstract

Theoretical description of particle sedimentation in blood considering hematocrit: A 2nd generation mathematical model

Berry,

Kralj-Iglič

2023

Advances in Biomembranes and Lipid Self-Assembly

View full text Add to dashboard Cite

Autologous Platelet and Extracellular Vesicle-Rich Plasma as Therapeutic Fluid: A Review

Troha

Vozel

Arko

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

The preparation of autologous platelet and extracellular vesicle-rich plasma (PVRP) has been explored in many medical fields with the aim to benefit from its healing potential. In parallel, efforts are being invested to understand the function and dynamics of PVRP that is complex in its composition and interactions. Some clinical evidence reveals beneficial effects of PVRP, while some report that there were no effects. To optimize the preparation methods, functions and mechanisms of PVRP, its constituents should be better understood. With the intention to promote further studies of autologous therapeutic PVRP, we performed a review on some topics regarding PVRP composition, harvesting, assessment and preservation, and also on clinical experience following PVRP application in humans and animals. Besides the acknowledged actions of platelets, leukocytes and different molecules, we focus on extracellular vesicles that were found abundant in PVRP.

show abstract

Treatment with platelet- and extracellular vesicle-rich plasma in otorhinolaryngology-a review and future perspectives

Cited by 4 publications

References 102 publications

Autologous Platelet- and Extracellular Vesicle-Rich Plasma Is an Effective Treatment Modality for Chronic Postoperative Temporal Bone Cavity Inflammation: Randomized Controlled Clinical Trial

Autologous Platelet- and Extracellular Vesicle-Rich Plasma Is an Effective Treatment Modality for Chronic Postoperative Temporal Bone Cavity Inflammation: Randomized Controlled Clinical Trial

Theoretical description of particle sedimentation in blood considering hematocrit: A 2nd generation mathematical model

Autologous Platelet and Extracellular Vesicle-Rich Plasma as Therapeutic Fluid: A Review

Contact Info

Product

Resources

About